---
title: "IRON.US (IRON.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/IRON.US/news.md"
symbol: "IRON.US"
name: "IRON.US"
parent: "https://longbridge.com/zh-CN/quote/IRON.US.md"
datetime: "2026-03-15T09:45:26.695Z"
locales:
  - [en](https://longbridge.com/en/quote/IRON.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IRON.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IRON.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/IRON.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/IRON.US/news.md)


# IRON.US (IRON.US) — 相关新闻

### [IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm](https://longbridge.com/zh-CN/news/279133165.md)
*2026-03-14T21:55:28.000Z*
> The Schall Law Firm is investigating claims on behalf of investors of Disc Medicine, Inc. (NASDAQ: IRON) for potential v

### [A Look At Disc Medicine (IRON) Valuation After Recent Share Price Swings](https://longbridge.com/zh-CN/news/277316748.md)
*2026-02-28T16:18:03.000Z*
> Disc Medicine (IRON) has experienced significant share price fluctuations, including a recent decline of 16.74% over 30 

### [Disc Medicine (NASDAQ:IRON) CFO Sells $24,378.18 in Stock](https://longbridge.com/zh-CN/news/277311390.md)
*2026-02-28T14:28:39.000Z*
> Disc Medicine CFO Jean Franchi sold 353 shares at $69.06, totaling $24,378.18, reducing ownership by 0.49% to 70,990 sha

### [Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results](https://longbridge.com/zh-CN/news/277129320.md)
*2026-02-27T02:04:47.000Z*
> Disc Medicine (NASDAQ:IRON) reported quarterly earnings of ($1.62) per share, exceeding analysts' expectations of ($1.69

### [Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results](https://longbridge.com/zh-CN/news/277052357.md)
*2026-02-26T13:43:00.000Z*
> Disc Medicine reported its financial results for Q4 and full year 2025, showing a net loss of $212.2 million, up from $1

### [Disc Medicine | 8-K: FY2025 Revenue: USD 0](https://longbridge.com/zh-CN/news/277050072.md)
*2026-02-26T13:34:55.000Z*
### [Disc Medicine to Seek Traditional FDA Approval for Bitopertin After EPP CRL; APOLLO Data Due Q4](https://longbridge.com/zh-CN/news/276646467.md)
*2026-02-23T21:27:23.000Z*
> Disc Medicine (NASDAQ:IRON) plans to pursue traditional FDA approval for bitopertin in erythropoietic protoporphyria (EP

### [Disc Medicine (IRON) Receives a Buy from LifeSci Capital](https://longbridge.com/zh-CN/news/276517296.md)
*2026-02-21T15:35:35.000Z*
> LifeSci Capital analyst Rami Katkhuda has maintained a Buy rating on Disc Medicine (NASDAQ: IRON) with a price target of

### [Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020](https://longbridge.com/zh-CN/news/276453426.md)
*2026-02-20T14:34:00.000Z*
> This week in biotech, significant milestones were achieved, including FDA approvals and licensing agreements. NRx Pharma

### [20:06 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON](https://longbridge.com/zh-CN/news/276398337.md)
*2026-02-20T01:07:19.000Z*
> Pomerantz Law Firm is investigating claims on behalf of investors of Disc Medicine, Inc. (NASDAQ: IRON) regarding potent